Clinical and Diagnostic Laboratory Immunology, November 2001, p. 1044-1048, Vol. 8, No. 6
1071-412X/01/$04.00+0 DOI: 10.1128/CDLI.8.6.1044-1048.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Veterans Affairs Medical Center and Department of Surgery, University of Louisville School of Medicine, Louisville, Kentucky 40292
Received 8 March 2001/Returned for modification 9 May 2001/Accepted 18 July 2001
| |
ABSTRACT |
|---|
|
|
|---|
The signal transducer and activator of transcription factor 4 (STAT4) pathway mediates the intracellular effects of interleukin-12 (IL-12), leading to the production of gamma interferon, induction of a
T helper type 1 response, and increased natural killer cell cytotoxicity. The purpose of this study was to determine the role of
the STAT4 pathway during polymicrobial peritonitis in the cecal ligation and puncture (CLP) model. CLP was performed on STAT4-deficient (STAT4
/
) and wild-type control (BALB/c) mice. At 4 h after CLP, STAT4
/
mice had significantly higher
bacterial counts in the peritoneal lavage fluid, liver, and blood. This
difference persisted for 18 h in the peritoneal lavage fluid and
blood. Neutrophil migration to the site of infection and into remote
tissues was unaffected. Despite higher bacterial counts locally and
systemically, STAT4
/
mice had a lower mortality rate
than BALB/c controls. In contrast, blockade of IL-12 in BALB/c mice was
detrimental to host survival. A blunted serum IL-12 response at 18 h after CLP was exhibited in STAT4
/
mice. These results
suggest several critical roles for the STAT4 pathway in the resolution
of polymicrobial infections. Additionally, the disparate effects
observed with IL-12 blockade and STAT4 deficiency on host survival
suggest that IL-12 may activate alternate pathways promoting survival.
| |
INTRODUCTION |
|---|
|
|
|---|
Signal transducers and activators of
transcription (STAT) transmit cytokine signals to the nucleus,
facilitating gene transcription (19). Six different STAT
proteins have been identified, each with its own array of cytokine
specificities and resultant gene activations (19). The
STAT factor 4 (STAT4) protein was originally cloned through its
homology with previously described STAT proteins (43, 45)
and is activated in T cells, natural killer cells, testis, and thymus
in response to interleukin-12 (IL-12) (42). Interaction of
IL-12 with its cell surface receptor leads to phosphorylation of STAT4
by receptor-associated Janus kinases. Once phosphorylated, STAT4
dimerizes and translocates to the nucleus and promotes gene transcription yielding production of gamma interferon (IFN-
), development of the T helper type 1 response, and increased natural killer cell cytotoxicity (25, 39). The host immune
response to infections therefore relies to some extent on IL-12 and STAT4.
Sepsis is characterized by an inflammatory cytokine response, including production of IL-12 (22). Supplemental IL-12 can improve host bacterial resistance, and deficiency of IL-12 predisposes patients to bacterial infections and sepsis (11, 17). When combined with IL-18 or IL-2, administration of IL-12 can induce a fatal response in mice similar to septic shock (3, 4). Additionally, IL-12 administration in humans has resulted in organ damage, hemodynamic instability, and death (7). These studies suggest an important role for IL-12 (and STAT4 by association) in survival, bacterial clearance, and organ failure during bacterial sepsis.
The aim of the present study was to examine the role of the STAT4 pathway during sepsis by using the clinically relevant cecal ligation and puncture (CLP) model (31, 33). We demonstrate a survival benefit and impaired bacterial clearance when the host lacks STAT4. Parallel studies of IL-12 neutralization and STAT4 deficiency suggest that the antibacterial effects of IL-12 are mediated by STAT4. However, these data also suggest that despite its antibacterial effects, STAT4 activation is detrimental to host survival.
(This work was initially presented at the Surgical Infection Society meeting at Snowbird, Utah, on 3 May 2001.)
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Animals.
Six- to 8-week-old STAT4
/
mice
(BALB/c-Stat4tm1Gru mice deficient in the STAT4
protein) and their wild-type controls (BALB/c mice) were used (Jackson
Laboratories, Bar Harbor, Maine). Animals were housed in a facility
approved by the American Association for Accreditation of Laboratory
Animal Care and were provided food and water ad libitum. Studies were
conducted in accordance with the guidelines of the National Institutes
of Health and under the supervision of a veterinarian.
CLP. Mice were anesthetized with ketamine (80 mg/kg) and xylazine (16 mg/kg) by intramuscular injection. CLP was performed as follows. The cecum was exposed through a midline laparotomy incision and ligated just below the ileocecal junction with 4-0 silk suture. For survival and 18-h harvest experiments, a single 23-gauge puncture was made in the cecum. For 4-h harvest experiments to yield higher bacterial counts, two 18-gauge punctures were made in the cecum. The cecum was then returned into the peritoneal cavity, and the abdominal incision was closed in layers.
Survival. Mice were injected with 1 ml of normal saline subcutaneously for volume resuscitation at the time of CLP. Cefoxitin (100 mg/kg) was administered subcutaneously every 12 h. For IL-12 immunoneutralization experiments, 200 µg of either IL-12 antibody or control immunoglobulin G (R&D Systems, Minneapolis, Minn.) was injected into the tail vein immediately prior to CLP.
Timed harvests. Anesthetized mice were killed at 4 or 18 h after CLP. Peritoneal lavage fluid was obtained for determination of bacterial counts, cytokine levels, neutrophil counts, and myeloperoxidase levels. Liver, lung, and spleen tissues were collected for determination of bacterial counts and myeloperoxidase levels. Blood was collected by cardiac puncture for evaluation of bacterial and leukocyte counts.
Peritoneal lavage. Peritoneal exudate cells were recovered by peritoneal lavage with 4 ml of ice-cold heparinized RPMI 1640 medium (Gibco-BRL, Bethesda, Md.) and were counted manually by hemacytometer.
Myeloperoxidase assay. Myeloperoxidase was used as a measure of neutrophil accumulation. Liver, lung, and spleen tissues were homogenized in dilute phosphate buffer and then centrifuged at 10,000 rpm for 15 min. Peritoneal cells were collected through centrifugation of the peritoneal lavage collection. The pellets of the tissues and peritoneal cells were solubilized in a phosphate buffer containing a mild detergent. After freezing, thawing, and sonication, the solubilized pellets were heated for 2 h at 60°C. The myeloperoxidase level was determined spectrophotometrically by using tetramethylbenzidine as the color reagent.
Cytokine assays.
Concentration of IL-6, IL-12, and IFN-
in the serum and supernatant of the peritoneal lavage were determined
by enzyme-linked immunosorbent assays (Biosource International,
Camarillo, Calif.) performed according to the manufacturer's instructions.
Bacterial counts. Homogenized liver, lung, and spleen tissues (150 to 250 mg in 2 ml of sterile saline), whole blood, and peritoneal lavage fluid were plated in serial log dilutions on tryptic soy or brain heart infusion agar plates. After plating, tryptic soy agar plates were incubated at 37°C aerobically for 24 h, and brain heart infusion agar plates were incubated anaerobically for 48 h. Results are expressed as CFU per milliliter for blood, CFU per gram for tissues, and CFU per mouse for the peritoneal lavage fluid.
Statistical analysis. Concentrations of cytokines, neutrophil counts, and myeloperoxidase levels were compared by analysis of variance followed by the Tukey-Kramer HSD test. The Fisher exact test was used for differences in survival. Bacterial counts were compared nonparametrically using the Mann-Whitney U test. Cytokine and myeloperoxidase levels are expressed as means ± standard error of the mean (SEM). A P value of 0.05 or less was considered significant.
| |
RESULTS |
|---|
|
|
|---|
Disparate effects on survival after CLP with STAT4
deficiency and IL-12 neutralization.
To assess the participation
of the STAT4 pathway in the pathophysiological effects of polymicrobial
sepsis, STAT4
/
and matched BALB/c control mice were
subjected to CLP. Among the BALB/c controls, 90% of all mice were dead
within 4 days (Fig. 1). STAT4 nullizygous
mice displayed a significant increase in survival after CLP
(P = 0.02), with only 50% dead by 6 days.
|
|
Higher bacterial counts after CLP in STAT4
/
mice.
To quantify the ability of the host to clear the bacterial
challenge, bacterial counts were determined at the site of the infection, in the blood, and in remote tissues. At 4 h after CLP, aerobic counts were significantly higher in STAT4
/
mice
in the peritoneal lavage fluid, liver, and blood (P < 0.05) (Fig. 3A). Anaerobic counts
were significantly higher in the liver tissue (P < 0.05) (Fig. 3B). The liver was the only tissue sampled that had
reliably detectable counts, which is consistent with observations that
bacteria in the bloodstream ultimately accumulate in the liver
(15, 35).
|
/
mice had significantly higher aerobic bacterial
counts in the peritoneal lavage fluid, blood, and liver tissue
(P = 0.05) (Fig. 4A).
Anaerobic counts were significantly higher in the peritoneal lavage
fluid and blood (P = 0.05) (Fig. 4B), whereas liver
anaerobic counts were below the limit of detection in both groups (not
shown). At both 4 and 18 h, all of the colonies were
morphologically similar. The species types have been described
previously by McMasters et al. (28).
|
Neutrophil migration patterns are similar in
STAT4
/
and BALB/c control mice.
We evaluated
myeloperoxidase levels in the lung, liver, spleen, and peritoneal
exudate cells and determined microscopic neutrophil counts in the blood
and peritoneal lavage fluid to detect changes in neutrophil
trafficking. There were no significant differences in neutrophil
accumulation to account for the differences in survival or bacterial
counts (Table 1). Concordantly, cell
counts in the peritoneal lavage fluid and blood were not significantly
different (data not shown).
|
Cytokine determinations.
Dysregulation of IL-12 has been
associated with injury, and supplemental IL-12 in this setting has been
beneficial (11). To assess whether changes in IL-12 levels
accounted for differences in survival or bacterial counts, IL-12 levels
were measured in the serum and peritoneal lavage fluid. At 18 h,
BALB/c control mice showed a significant increase in serum IL-12 levels
compared with baseline (P < 0.05) (Fig.
5). Unexpectedly, no increase was detected in the serum from STAT4
/
mice. Surprisingly,
not only did the STAT4
/
mice have improved survival
after CLP, where IL-12 might be expected to be protective, these mice
also had higher bacterial levels that have been correlated with higher
IL-12 levels (6, 8, 32). Peritoneal IL-12 levels did not
differ from those in control mice.
|
/
mice were compared with BALB/c mice (data not
shown). IL-6 is a cytokine previously found to be predictive of outcome
after shock (30). At 18 h after CLP in three
wild-type control mice, IFN-
levels in the peritoneal lavage fluid
and serum were 65 ± 21 pg/ml and 80 ± 16 pg/ml,
respectively. These levels of IFN-
approach the limit of detection
of the assay, limiting the utility for comparing experimental groups, a
finding similar to previous observations (34).
| |
DISCUSSION |
|---|
|
|
|---|
IL-12 is the principal activator of STAT4 (19, 42). Deficiency of STAT4 and immunoneutralization of IL-12 would therefore be expected to have the same effects. Quite unexpectedly, we observed opposite effects on survival with IL-12 blockade and STAT4 deficiency after CLP. Alternate pathways activated by IL-12 and for other activators of STAT4 may explain these effects.
IFN-
was one of the first described alternative activators of STAT4
in a human cell line (5). Since then, IL-2 has been shown
to activate STAT4 in natural killer cells but not T cells (41), and IL-17 can activate STAT4 in human leukemia cells
(37). Additionally, translocation of STAT4 to the nucleus
has been observed in vascular smooth muscle cells in response to
activation of urokinase-type plasminogen activator receptor
(9). All of these mediators could function during a septic
challenge in the face of IL-12 blockade, but their effects may be
abrogated in STAT4
/
mice.
IL-12 also has the potential to exert effects during sepsis when
STAT4 is not present. Activation of STAT1, STAT3, and STAT5 can occur
in response to IL-12 in Th1-differentiated lymphocytes, providing
alternate STAT pathways for IL-12 (12, 20). Nuclear factor
kappa B (NF-
B) translocates to the nucleus in response to IL-12 in
dendritic cells and is associated with a structurally different IL-12
receptor than in T cells (16). It is not clear to what
extent each of these alternate pathways function during polymicrobial
sepsis, or whether they account for the effects observed in the present
study. It is apparent from our data, however, that IL-12 may not signal
solely through STAT4 and that STAT4 has divergent effects itself,
promoting antibacterial defense while increasing the rate of mortality.
The effects of IL-12 blockade and STAT4 deficiency on bacterial
clearance in polymicrobial peritonitis are more congruent. IL-12 is
known to be important in host defense against mono- and polymicrobial
infections (10, 14, 29), and immunoneutralization of IL-12
prior to CLP impairs peritoneal bacterial clearance (36). Given the close association of IL-12 and STAT4 activation, the impaired
clearance of bacteria observed in STAT4 deficiency is not surprising.
Others have shown that STAT4
/
mice exhibit increased
parasitemia when infected with Trypanosoma cruzi
(38). However, a patient with intact STAT4 activation but
impaired STAT1, STAT3, and STAT5 activation in response to IL-12 with
recurrent Staphylococcus aureus and Mycobacterium
avium infections has been described (13). This raises
the possibility that the antibacterial effects of IL-12 are elicited
primarily through pathways not involving STAT4.
Surprisingly, survival after CLP in STAT4
/
mice
did not correlate with the higher observed bacterial counts. A similar
combination of worsened bacterial clearance and improved bacterial
tolerance was noted with IL-12 immunoneutralization prior to
intraperitoneal Escherichia coli administration
(46). Although there is a suggested increase in bacterial
tolerance in STAT4
/
mice during CLP, we cannot exclude
the possibility of altered bacterial composition or virulence even
though the morphology of the colonies was similar in both groups. Our
data confirm that signaling via STAT4 is an important aspect of the
host's mechanism in clearing bacteria.
Bacterial products, including lipopolysaccharide, lipoteichoic acid,
and bacterial DNA, induce IL-12 production (6, 8, 32).
Because of higher bacterial counts, mice deficient in STAT4 would be
expected to have higher IL-12 levels. Instead, we observed an
attenuated serum IL-12 response after CLP in STAT4
/
mice. IFN-
is produced in response to IL-12 and STAT4 activation and
can further induce IL-12 production (18, 27). Interference with this positive feedback loop is one explanation of the apparently counterintuitive effect of the muted IL-12 response demonstrated in
STAT4
/
mice. Spleen cells from STAT4
/
mice are unable to generate IFN-
in response to IL-12 in vitro, lending further support to the proposed mechanism (39).
Confirmation of an attenuated IFN-
response during polymicrobial
peritonitis in STAT4
/
mice is limited, however, because
measurable levels of IFN-
in vivo approximate the limit of detection
of the assay (34).
Neutrophil migration and activation are implicated in the pathogenesis
of organ failure during sepsis, and therefore alterations in neutrophil
trafficking are pivotal (1, 21, 26, 40). Th1 cells,
induced mainly but not exclusively through a STAT4-dependent process
(23, 24, 39), express chemokine receptors differently from
Th2 cells (2). The secretion of chemokines also differs between Th1 cells and Th2 cells (44), suggesting a
possible role for a STAT4-dependent mechanism of neutrophil
recruitment. We observed no differences in neutrophil migration to
account for the observed effects on bacterial counts or survival. This observation is corroborated by in vitro experiments demonstrating intact chemokine secretion in Th1 cells from STAT4
/
mice (44).
In summary, STAT4 participates in several important ways during
polymicrobial sepsis, including eradicating bacteria, regulating IL-12
levels, and affecting survival. Based on our data, it appears that
IL-12 mediates bacterial clearance via activation of STAT4 during CLP.
However, blockade of IL-12 results in decreased survival, whereas
STAT4
/
mice display increased survival. These findings
suggest that STAT4 activation is detrimental to host survival and that
IL-12 may activate other signaling pathways that promote survival.
Further investigation into the nuances of STAT4 and IL-12 function and application of this knowledge to sepsis may ultimately reveal an
intervention allowing increased survival without adversely affecting
bacterial clearance.
| |
ACKNOWLEDGMENTS |
|---|
This material is based on work supported by the Office of Research and Development, Department of Veterans Affairs.
We acknowledge the expert technical assistance of Sarah Gardner.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Department of Surgery, University of Louisville, Louisville, KY 40292. Phone: (502) 852-6230. Fax: (502) 852-8915. E-mail: wgchea01{at}athena.louisville.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Bellingan, G.
1999.
Inflammatory cell activation in sepsis.
Br. Med. Bull.
55:12-29 |
| 2. |
Bonecchi, R.,
G. Bianchi,
P. P. Bordignon,
D. D'Ambrosio,
R. Lang,
A. Borsatti,
S. Sozzani,
P. Allavena,
P. A. Gray,
A. Mantovani, and F. Sinigaglia.
1998.
Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s.
J. Exp. Med.
187:129-134 |
| 3. |
Carson, W. E.,
J. E. Dierksheide,
S. Jabbour,
M. Anghelina,
P. Bouchard,
G. Ku,
H. Yu,
H. Baumann,
M. H. Shah,
M. A. Cooper,
J. Durbin, and M. A. Caligiuri.
2000.
Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: critical role of natural killer cell interferon-gamma production and STAT-mediated signal transduction.
Blood
96:1465-1473 |
| 4. |
Carson, W. E.,
H. Yu,
J. Dierksheide,
K. Pfeffer,
P. Bouchard,
R. Clark,
J. Durbin,
A. S. Baldwin,
J. Peschon,
P. R. Johnson,
G. Ku,
H. Baumann, and M. A. Caligiuri.
1999.
A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells.
J. Immunol.
162:4943-4951 |
| 5. | Cho, S. S., C. M. Bacon, C. Sudarshan, R. C. Rees, D. Finbloom, R. Pine, and J. J. O'Shea. 1996. Activation of STAT4 by IL-12 and IFN-alpha: evidence for the involvement of ligand-induced tyrosine and serine phosphorylation. J. Immunol. 157:4781-4789[Abstract]. |
| 6. | Cleveland, M. G., J. D. Gorham, T. L. Murphy, E. Tuomanen, and K. M. Murphy. 1996. Lipoteichoic acid preparations of gram-positive bacteria induce interleukin-12 through a CD14-dependent pathway. Infect. Immun. 64:1906-1912[Abstract]. |
| 7. | Cohen, J. 1995. IL-12 deaths: explanation and a puzzle. Science 270:908. |
| 8. |
D'Andrea, A.,
M. Rengaraju,
N. M. Valiante,
J. Chehimi,
M. Kubin,
M. Aste,
S. H. Chan,
M. Kobayashi,
D. Young, and E. Nickbarg.
1992.
Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells.
J. Exp. Med.
176:1387-1398 |
| 9. |
Dumler, I.,
A. Kopmann,
K. Wagner,
O. A. Mayboroda,
U. Jerke,
R. Dietz,
H. Haller, and D. C. Gulba.
1999.
Urokinase induces activation and formation of Stat4 and Stat1-Stat2 complexes in human vascular smooth muscle cells.
J. Biol. Chem.
274:24059-24065 |
| 10. | Flynn, J. L., M. M. Goldstein, K. J. Triebold, J. Sypek, S. Wolf, and B. R. Bloom. 1995. IL-12 increases resistance of BALB/c mice to Mycobacterium tuberculosis infection. J. Immunol. 155:2515-2524[Abstract]. |
| 11. | Goebel, A., E. Kavanagh, A. Lyons, I. B. Saporoschetz, C. Soberg, J. A. Lederer, J. A. Mannick, and M. L. Rodrick. 2000. Injury induces deficient interleukin-12 production, but interleukin-12 therapy after injury restores resistance to infection. Ann. Surg. 231:253-261[CrossRef][Medline]. |
| 12. |
Gollob, J. A.,
E. A. Murphy,
S. Mahajan,
C. P. Schnipper,
J. Ritz, and D. A. Frank.
1998.
Altered interleukin-12 responsiveness in Th1 and Th2 cells is associated with the differential activation of STAT5 and STAT1.
Blood
91:1341-1354 |
| 13. |
Gollob, J. A.,
K. G. Veenstra,
H. Jyonouchi,
A. M. Kelly,
P. Ferrieri,
D. J. Panka,
F. Altare,
C. Fieschi,
J. L. Casanova,
D. A. Frank, and J. W. Mier.
2000.
Impairment of STAT activation by IL-12 in a patient with atypical mycobacterial and staphylococcal infections.
J. Immunol.
165:4120-4126 |
| 14. | Greenberger, M. J., S. L. Kunkel, R. M. Strieter, N. W. Lukacs, J. Bramson, J. Gauldie, F. L. Graham, M. Hitt, J. M. Danforth, and T. J. Standiford. 1996. IL-12 gene therapy protects mice in lethal Klebsiella pneumonia. J. Immunol. 157:3006-3012[Abstract]. |
| 15. | Gregory, S. H., L. K. Barczynski, and E. J. Wing. 1992. Effector function of hepatocytes and Kupffer cells in the resolution of systemic bacterial infections. J. Leukoc. Biol. 51:421-424[Abstract]. |
| 16. | Grohmann, U., M. L. Belladonna, R. Bianchi, C. Orabona, E. Ayroldi, M. C. Fioretti, and P. Puccetti. 1998. IL-12 acts directly on DC to promote nuclear localization of NF-kappaB and primes DC for IL-12 production. Immunity 9:315-323[CrossRef][Medline]. |
| 17. |
Haraguchi, S.,
N. K. Day,
R. P. Nelson, Jr.,
P. Emmanuel,
J. E. Duplantier,
C. S. Christodoulou, and R. A. Good.
1998.
Interleukin 12 deficiency associated with recurrent infections.
Proc. Natl. Acad. Sci. USA
95:13125-13129 |
| 18. |
Hayes, M. P.,
J. Wang, and M. A. Norcross.
1995.
Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes.
Blood
86:646-650 |
| 19. | Imada, K., and W. J. Leonard. 2000. The Jak-STAT pathway. Mol. Immunol. 37:1-11[CrossRef][Medline]. |
| 20. |
Jacobson, N. G.,
S. J. Szabo,
R. M. Weber-Nordt,
Z. Zhong,
R. D. Schreiber,
J. E. Darnell, Jr., and K. M. Murphy.
1995.
Interleukin 12 signaling in T helper type 1 (Th1) cells involves tyrosine phosphorylation of signal transducer and activator of transcription (Stat)3 and Stat4.
J. Exp. Med.
181:1755-1762 |
| 21. | Jaeschke, H., and C. W. Smith. 1997. Mechanisms of neutrophil-induced parenchymal cell injury. J. Leukoc. Biol. 61:647-653[Abstract]. |
| 22. |
Jansen, P. M.,
T. C. van der Pouw Kraan,
I. W. de Jong,
G. van Mierlo,
J. Wijdenes,
A. A. Chang,
L. A. Aarden,
F. B. Taylor, Jr., and C. E. Hack.
1996.
Release of interleukin-12 in experimental Escherichia coli septic shock in baboons: relation to plasma levels of interleukin-10 and interferon-gamma.
Blood
87:5144-5151 |
| 23. | Kaplan, M. H., and M. J. Grusby. 1998. Regulation of T helper cell differentiation by STAT molecules. J. Leukoc. Biol. 64:2-5[Abstract]. |
| 24. | Kaplan, M. H., Y. L. Sun, T. Hoey, and M. J. Grusby. 1996. Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice. Nature 382:174-177[CrossRef][Medline]. |
| 25. |
Lawless, V. A.,
S. Zhang,
O. N. Ozes,
H. A. Bruns,
I. Oldham,
T. Hoey,
M. J. Grusby, and M. H. Kaplan.
2000.
Stat4 regulates multiple components of IFN-gamma-inducing signaling pathways.
J. Immunol.
165:6803-6808 |
| 26. | Lehr, H. A., F. Bittinger, and C. J. Kirkpatrick. 2000. Microcirculatory dysfunction in sepsis: a pathogenetic basis for therapy? J. Pathol. 190:373-386[CrossRef][Medline]. |
| 27. |
Ma, X.,
J. M. Chow,
G. Gri,
G. Carra,
F. Gerosa,
S. F. Wolf,
R. Dzialo, and G. Trinchieri.
1996.
The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells.
J. Exp. Med.
183:147-157 |
| 28. | McMasters, K. M., J. C. Peyton, D. J. Hadjiminas, and W. G. Cheadle. 1994. Endotoxin and tumor necrosis factor do not cause mortality from cecal ligation and puncture. Cytokine 6:530-536[CrossRef][Medline]. |
| 29. | Metzger, D. W., R. Raeder, V. H. Van Cleave, and M. D. Boyle. 1995. Protection of mice from group A streptococcal skin infection by interleukin-12. J. Infect. Dis. 171:1643-1645[Medline]. |
| 30. |
Pinsky, M. R.,
J. L. Vincent,
J. Deviere,
M. Alegre,
R. J. Kahn, and E. Dupont.
1993.
Serum cytokine levels in human septic shock: relation to multiple-system organ failure and mortality.
Chest
103:565-575 |
| 31. | Remick, D. G., D. E. Newcomb, G. L. Bolgos, and D. R. Call. 2000. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock 13:110-116[Medline]. |
| 32. | Sato, Y., M. Roman, H. Tighe, D. Lee, M. Corr, M. D. Nguyen, G. J. Silverman, M. Lotz, D. A. Carson, and E. Raz. 1996. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 273:352-354[Abstract]. |
| 33. | Shrotri, M. S., J. C. Peyton, and W. G. Cheadle. 1999. Mouse peritonitis model using cecal ligation and puncture, p. 173-181. In M. A. Sande, C. Carbon, B. Fantin, R. Kaminsky, E. R. Kern, and T. O'Reilly (ed.), Handbook of animal models of infection Academic Press, San Diego, Calif. |
| 34. |
Stamme, C.,
D. S. Bundschuh,
T. Hartung,
U. Gebert,
L. Wollin,
R. Nusing,
A. Wendel, and S. Uhlig.
1999.
Temporal sequence of pulmonary and systemic inflammatory responses to graded polymicrobial peritonitis in mice.
Infect. Immun.
67:5642-5650 |
| 35. | Steel, D. M., and A. S. Whitehead. 1994. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol. Today 15:81-88[CrossRef][Medline]. |
| 36. |
Steinhauser, M. L.,
C. M. Hogaboam,
N. W. Lukacs,
R. M. Strieter, and S. L. Kunkel.
1999.
Multiple roles for IL-12 in a model of acute septic peritonitis.
J. Immunol.
162:5437-5443 |
| 37. | Subramaniam, S. V., R. S. Cooper, and S. E. Adunyah. 1999. Evidence for the involvement of JAK/STAT pathway in the signaling mechanism of interleukin-17. Biochem. Biophys. Res. Commun. 262:14-19[CrossRef][Medline]. |
| 38. |
Tarleton, R. L.,
M. J. Grusby, and L. Zhang.
2000.
Increased susceptibility of Stat4-deficient and enhanced resistance in Stat6-deficient mice to infection with Trypanosoma cruzi.
J. Immunol.
165:1520-1525 |
| 39. | Thierfelder, W. E., J. M. van Deursen, K. Yamamoto, R. A. Tripp, S. R. Sarawar, R. T. Carson, M. Y. Sangster, D. A. Vignali, P. C. Doherty, G. C. Grosveld, and J. N. Ihle. 1996. Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature 382:171-174[CrossRef][Medline]. |
| 40. | Wagner, J. G., and R. A. Roth. 1999. Neutrophil migration during endotoxemia. J. Leukoc. Biol. 66:10-24[Abstract]. |
| 41. |
Wang, K. S.,
J. Ritz, and D. A. Frank.
1999.
IL-2 induces STAT4 activation in primary NK cells and NK cell lines, but not in T cells.
J. Immunol.
162:299-304 |
| 42. | Wurster, A. L., T. Tanaka, and M. J. Grusby. 2000. The biology of Stat4 and Stat6. Oncogene 19:2577-2584[CrossRef][Medline]. |
| 43. |
Yamamoto, K.,
F. W. Quelle,
W. E. Thierfelder,
B. L. Kreider,
D. J. Gilbert,
N. A. Jenkins,
N. G. Copeland,
O. Silvennoinen, and J. N. Ihle.
1994.
Stat4, a novel gamma interferon activation site-binding protein expressed in early myeloid differentiation.
Mol. Cell. Biol.
14:4342-4349 |
| 44. |
Zhang, S.,
N. W. Lukacs,
V. A. Lawless,
S. L. Kunkel, and M. H. Kaplan.
2000.
Cutting edge: differential expression of chemokines in Th1 and Th2 cells is dependent on Stat6 but not Stat4.
J. Immunol.
165:10-14 |
| 45. |
Zhong, Z.,
Z. Wen, and J. E. Darnell, Jr.
1994.
Stat3 and Stat4: members of the family of signal transducers and activators of transcription.
Proc. Natl. Acad. Sci. USA
91:4806-4810 |
| 46. | Zisman, D. A., S. L. Kunkel, R. M. Strieter, J. Gauldie, W. C. Tsai, J. Bramson, J. M. Wilkowski, K. A. Bucknell, and T. J. Standiford. 1997. Anti-interleukin-12 therapy protects mice in lethal endotoxemia but impairs bacterial clearance in murine Escherichia coli peritoneal sepsis. Shock 8:349-356[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Antimicrob. Agents Chemother. | Clin. Microbiol. Rev. | Infect. Immun. |
|---|---|---|
| J. Clin. Microbiol. | J. Virol. | ALL ASM JOURNALS |